title: Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy.
abstract: OBJECTIVE
  To evaluate the role of platin-based chemotherapy followed by salvage surgery in patients with recurrent ovarian cancer after negative second-look laparotomy.
  
  
  METHODS
  A retrospective chart review was conducted on 38 patients with recurrent ovarian cancer after a pathologic complete response to first-line chemotherapy. After diagnosis of recurrence all patients underwent retreatment with platin-based chemotherapy followed by radical salvage surgery.
  
  
  RESULTS
  Recurrent disease was diagnosed at a median interval of 22 months after second-look surgery. All patients had complete surgical debulking with no macroscopic tumor at the completion of the surgical procedure. Eight patients (21%) required an intestinal resection but no colostomy was performed. Two operative deaths occurred (5%). Twenty-two patients (58%) experienced a second recurrence after salvage surgery The median survival time for all patients after diagnosis of recurrent disease was 29 months (range 6-96 months), with nine patients (25%) surviving more than three years. Survival time after diagnosis of recurrence was not significantly related either to known prognostic factors of ovarian cancer or to the length of the clinical remission time.
  
  
  CONCLUSIONS
  Retreatment with platin-based chemotherapy followed by salvage surgery should be offered to recurrent ovarian cancer patients and would appear to prolong survival in a highly selected group of patients.
authors.affiliation: Department of Obstetrics and Gynecology, University of Milan, Istituto di Scienze Biomediche-Ospedale S. Gerardo-Monza, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Landoni
authors.forename: A
authors.initials: A
authors.lastname: Pellegrino
authors.forename: G
authors.initials: G
authors.lastname: Cormio
authors.forename: R
authors.initials: R
authors.lastname: Milani
authors.forename: A
authors.initials: A
authors.lastname: Maggioni
authors.forename: C
authors.initials: C
authors.lastname: Mangioni
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D012086:Reoperation; D016879:Salvage Therapy; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin